AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 1551535 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 240
Study 4089577 — intervention group
Group type: EXPERIMENTAL
Intervention: Highly purified duck embryo rabies vaccine (PDEV) administered according to WHO post-exposure schedule (6 injections on days 0, 3, 7, 14, 28, and 90)
Number of subjects: 0
Study 4089577 — intervention group
Group type: EXPERIMENTAL
Intervention: Highly purified duck embryo rabies vaccine (PDEV)
Number of subjects: 0
Study 31694682 — intervention group
Group type: EXPERIMENTAL
Intervention: Recruitment efforts using community ads and direct phone calls by study staff
Number of subjects: 140
Study 31694682 — intervention group
Group type: EXPERIMENTAL
Intervention: Qualitative evaluations of recruitment barriers
Number of subjects: 140
Study 28318872 — intervention group
Group type: EXPERIMENTAL
Intervention: 8 mg dexamethasone injection into the pterygomandibular space
Number of subjects: 31
Study 28318872 — intervention group
Group type: COMPARATOR
Intervention: Normal saline injection
Number of subjects: 31
Study 26216071 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher dose gefitinib (500 mg/d; H group)
Number of subjects: 100
Study 26216071 — intervention group
Group type: COMPARATOR
Intervention: Standard dose gefitinib (250 mg/d; S group)
Number of subjects: 100
Study 23336248 — intervention group
Group type: EXPERIMENTAL
Intervention: Opicapone 5, 10, 20 or 30 mg
Number of subjects: 0
Study 23336248 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 21315203 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril
Number of subjects: 5
Study 21315203 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5
Study 19619697 — intervention group
Group type: EXPERIMENTAL
Intervention: Impedance cardiography (ICG)
Number of subjects: 170
Study 16987384 — intervention group
Group type: EXPERIMENTAL
Intervention: Quinidine plus verapamil (Q+V) 480/240 mg/day
Number of subjects: 1033
Study 16987384 — intervention group
Group type: EXPERIMENTAL
Intervention: Quinidine plus verapamil (Q+V) 320/160 mg/day
Number of subjects: 1033
Study 16987384 — intervention group
Group type: EXPERIMENTAL
Intervention: Sotalol 320 mg/day
Number of subjects: 1033
Study 16987384 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1033
Study 16987384 — intervention group
Group type: EXPERIMENTAL
Intervention: Both antiarrhythmics (Q+V and sotalol)
Number of subjects: 1033
Study 12767414 — intervention group
Group type: EXPERIMENTAL
Intervention: Ginkgo (240 mg/d or 160 mg/d)
Number of subjects: 214
Study 12767414 — intervention group
Group type: COMPARATOR
Intervention: Placebo (0 mg/d)
Number of subjects: 214
Study 11074682 — intervention group
Group type: COMPARATOR
Intervention: Bed rest
Number of subjects: 1435
Study 11074682 — intervention group
Group type: COMPARATOR
Intervention: 2-3 days of bed rest
Number of subjects: 1435
Study 11074682 — intervention group
Group type: EXPERIMENTAL
Intervention: Advice to stay active
Number of subjects: 1435
Study 9159689 — intervention group
Group type: EXPERIMENTAL
Intervention: High-frequency capsulotomy (n = 27)
Number of subjects: 53
Study 9159689 — intervention group
Group type: COMPARATOR
Intervention: Continuous curvilinear capsulorhexis (CCC) (n = 26)
Number of subjects: 53
Study 8381800 — intervention group
Group type: EXPERIMENTAL
Intervention: Alprazolam 0.5 mg
Number of subjects: 14
Study 8381800 — intervention group
Group type: EXPERIMENTAL
Intervention: Alprazolam 2 mg
Number of subjects: 14
Study 8381800 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study 3120989 — intervention group
Group type: EXPERIMENTAL
Intervention: Fixed minidose warfarin (1 mg daily for mean 20 days)
Number of subjects: 104
Study 3120989 — intervention group
Group type: EXPERIMENTAL
Intervention: Full dose oral anticoagulation
Number of subjects: 104
Study 3120989 — intervention group
Group type: COMPARATOR
Intervention: No treatment (controls)
Number of subjects: 104
Study 3120989 — intervention group
Group type: EXPERIMENTAL
Intervention: Fixed minidose warfarin
Number of subjects: 104
Study 28500434 — intervention group
Group type: EXPERIMENTAL
Intervention: Coping Power (group) program
Number of subjects: 114
Study 28500434 — intervention group
Group type: COMPARATOR
Intervention: Individualized parent-child treatment
Number of subjects: 114
Study 26599569 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular benzathine benzylpenicillin (BPG)
Number of subjects: 508
Study 26599569 — intervention group
Group type: EXPERIMENTAL
Intervention: Twice daily co‐trimoxazole (SXT) for 3 days (4 mg/kg trimethoprim plus 20 mg/kg sulfamethoxazole per dose)
Number of subjects: 508
Study 26599569 — intervention group
Group type: EXPERIMENTAL
Intervention: Once daily SXT for 5 days (8 mg/kg trimethoprim plus 40 mg/kg sulfamethoxazole per dose)
Number of subjects: 508
Study 26599569 — intervention group
Group type: EXPERIMENTAL
Intervention: Pooled SXT groups
Number of subjects: 508
Study 26599569 — intervention group
Group type: COMPARATOR
Intervention: BPG group
Number of subjects: 508
Study 26631000 — intervention group
Group type: EXPERIMENTAL
Intervention: OB Nest intervention with 8 pre-planned office visits and 6 telephone or online nurse visits, plus home monitoring equipment.
Number of subjects: 0
Study 26631000 — intervention group
Group type: EXPERIMENTAL
Intervention: OB Nest intervention
Number of subjects: 0
Study 26631000 — intervention group
Group type: COMPARATOR
Intervention: Usual care with 12 pre-planned physician or midwife office visits.
Number of subjects: 0
Study 23394910 — intervention group
Group type: EXPERIMENTAL
Intervention: Herpes zoster vaccine administered by ophthalmologists
Number of subjects: 100
Study 23394910 — intervention group
Group type: COMPARATOR
Intervention: Patients who declined the herpes zoster vaccine
Number of subjects: 100
Study 23394910 — intervention group
Group type: COMPARATOR
Intervention: Reasons for declining the vaccine
Number of subjects: 100
Study 21957237 — intervention group
Group type: EXPERIMENTAL
Intervention: Perceptual learning variant of the serial reaction time task
Number of subjects: 0
Study 21957237 — intervention group
Group type: COMPARATOR
Intervention: Motor learning variant of the serial reaction time task
Number of subjects: 0
Study 18453305 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin
Number of subjects: 2326
Study 18453305 — intervention group
Group type: EXPERIMENTAL
Intervention: Warfarin
Number of subjects: 2326
Study 18453305 — intervention group
Group type: COMPARATOR
Intervention: Neither medication
Number of subjects: 2326
Study 16533874 — intervention group
Group type: EXPERIMENTAL
Intervention: Zoledronic acid
Number of subjects: 422
Study 16533874 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 422
Study 14662276 — intervention group
Group type: EXPERIMENTAL
Intervention: Rigid gas permeable (RGP) contact lenses
Number of subjects: 147
Study 14662276 — intervention group
Group type: EXPERIMENTAL
Intervention: Run-in period prior to randomized treatment-group assignment
Number of subjects: 147
Study 11153922 — intervention group
Group type: EXPERIMENTAL
Intervention: Dynamic/static tests
Number of subjects: 250
Study 11153922 — intervention group
Group type: COMPARATOR
Intervention: Other clinical tests (palpation, function tests)
Number of subjects: 250
Study 9106558 — intervention group
Group type: EXPERIMENTAL
Intervention: Medroxyprogesterone, 10 mg
Number of subjects: 7
Study 9106558 — intervention group
Group type: COMPARATOR
Intervention: Ethinyl estradiol, 50 microg
Number of subjects: 7
Study 8024639 — intervention group
Group type: EXPERIMENTAL
Intervention: Deflazacort (6 mg/tablet)
Number of subjects: 76
Study 8024639 — intervention group
Group type: COMPARATOR
Intervention: Prednisone (5 mg/tablet)
Number of subjects: 76
Study 8024639 — intervention group
Group type: EXPERIMENTAL
Intervention: Deflazacort
Number of subjects: 76
Study 8024639 — intervention group
Group type: COMPARATOR
Intervention: Prednisone
Number of subjects: 76
Study 8024639 — intervention group
Group type: EXPERIMENTAL
Intervention: Deflazacort and Prednisone
Number of subjects: 76
Study 2637388 — intervention group
Group type: EXPERIMENTAL
Intervention: diazepam 5 mg
Number of subjects: 16
Study 2637388 — intervention group
Group type: EXPERIMENTAL
Intervention: amobarbital 80 mg
Number of subjects: 16
Study 2637388 — intervention group
Group type: EXPERIMENTAL
Intervention: methylphenidate 15 mg
Number of subjects: 16
Study 2637388 — intervention group
Group type: EXPERIMENTAL
Intervention: placebo
Number of subjects: 16
Study 2637388 — intervention group
Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 16
Study 1157671 — intervention group
Group type: EXPERIMENTAL
Intervention: Econazole administered as vaginal cream (1077 patients)
Number of subjects: 2103
Study 1157671 — intervention group
Group type: EXPERIMENTAL
Intervention: Econazole administered in ovules (1026 patients)
Number of subjects: 2103
Study 31895636 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients not asked about financial concerns by hospital staff
Number of subjects: 50
Study 31895636 — intervention group
Group type: EXPERIMENTAL
Intervention: Family members not asked about financial concerns by hospital staff
Number of subjects: 50
Study 31895636 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients favoring receiving information about financial services after ICU stay
Number of subjects: 50
Study 31895636 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients preferring receiving information about financial services in ICU
Number of subjects: 50
Study 31895636 — intervention group
Group type: EXPERIMENTAL
Intervention: Family members preferring receiving information about financial services during ICU stay
Number of subjects: 50
Study 31895636 — intervention group
Group type: EXPERIMENTAL
Intervention: Family members preferring receiving information about financial services after ICU stay
Number of subjects: 50
Study 27646462 — intervention group
Group type: EXPERIMENTAL
Intervention: Interpersonal Psychotherapy‐Adolescent Skills Training
Number of subjects: 186
Study 27646462 — intervention group
Group type: COMPARATOR
Intervention: Group counseling
Number of subjects: 186
Study 29046273 — intervention group
Group type: EXPERIMENTAL
Intervention: Upright position
Number of subjects: 3093
Study 29046273 — intervention group
Group type: COMPARATOR
Intervention: Lying down position
Number of subjects: 3093
Study 25483416 — intervention group
Group type: EXPERIMENTAL
Intervention: Belinostat plus azacitidine (AZA)
Number of subjects: 56
Study 25483416 — intervention group
Group type: COMPARATOR
Intervention: Azacitidine (AZA) alone
Number of subjects: 56
Study 24739290 — intervention group
Group type: EXPERIMENTAL
Intervention: Static Stretching (SS)
Number of subjects: 18
Study 24739290 — intervention group
Group type: EXPERIMENTAL
Intervention: Dynamic Stretching (DS)
Number of subjects: 18
Study 24739290 — intervention group
Group type: EXPERIMENTAL
Intervention: Increasing volume of warm-up (4, 8, and 12 sets)
Number of subjects: 18
Study 24739290 — intervention group
Group type: COMPARATOR
Intervention: Comparison between SS and DS
Number of subjects: 18
Study 24739290 — intervention group
Group type: COMPARATOR
Intervention: No stretching treatment
Number of subjects: 18
Study 23002121 — intervention group
Group type: EXPERIMENTAL
Intervention: Assisted group (experts with assistants)
Number of subjects: 8
Study 23002121 — intervention group
Group type: COMPARATOR
Intervention: Control group (experts without assistants)
Number of subjects: 8
Study 19717846 — intervention group
Group type: EXPERIMENTAL
Intervention: Ticagrelor (180-mg loading dose, 90 mg twice daily thereafter)
Number of subjects: 18624
Study 19717846 — intervention group
Group type: COMPARATOR
Intervention: Clopidogrel (300-to-600-mg loading dose, 75 mg daily thereafter)
Number of subjects: 18624
Study 19717846 — intervention group
Group type: EXPERIMENTAL
Intervention: Ticagrelor
Number of subjects: 18624
Study 19717846 — intervention group
Group type: COMPARATOR
Intervention: Clopidogrel
Number of subjects: 18624
Study 17697303 — intervention group
Group type: EXPERIMENTAL
Intervention: Norepinephrine at MAP of 65 mmHg
Number of subjects: 8
Study 17697303 — intervention group
Group type: EXPERIMENTAL
Intervention: Norepinephrine at MAP of 85 mmHg
Number of subjects: 8
Study 15131454 — intervention group
Group type: EXPERIMENTAL
Intervention: Specific stabilizing exercises for pelvic girdle pain
Number of subjects: 81
Study 15131454 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified treatment)
Number of subjects: 81
Study 12658810 — intervention group
Group type: EXPERIMENTAL
Intervention: Clavulanate Potassium and Amoxicillin (1:7) dispersible tablets (Tested formulation, T)
Number of subjects: 18
Study 12658810 — intervention group
Group type: COMPARATOR
Intervention: Augmentin syrup (Reference formulation, R)
Number of subjects: 18
Study 9674880 — intervention group
Group type: EXPERIMENTAL
Intervention: Video-based training, prompts installed in the pharmacy, group-based feedback on counseling rates
Number of subjects: 178
Study 7488579 — intervention group
Group type: EXPERIMENTAL
Intervention: 78 dioptre lens
Number of subjects: 29
Study 7488579 — intervention group
Group type: EXPERIMENTAL
Intervention: Optic disc biometer
Number of subjects: 29
Study 7488579 — intervention group
Group type: COMPARATOR
Intervention: Comparison of both methods
Number of subjects: 29
Study 2287055 — intervention group
Group type: EXPERIMENTAL
Intervention: S 6472 (750 mg twice daily for 5 days)
Number of subjects: 280
Study 2287055 — intervention group
Group type: COMPARATOR
Intervention: Conventional cefaclor preparation (CCL) (500 mg three times daily for 5 days)
Number of subjects: 280
Study 2287055 — intervention group
Group type: EXPERIMENTAL
Intervention: S 6472
Number of subjects: 280
Study 2287055 — intervention group
Group type: COMPARATOR
Intervention: CCL
Number of subjects: 280
Study 6988033 — intervention group
Group type: EXPERIMENTAL
Intervention: Transverse incisions
Number of subjects: 579
Study 6988033 — intervention group
Group type: COMPARATOR
Intervention: Midline incisions
Number of subjects: 579
Study 31650182 — intervention group
Group type: EXPERIMENTAL
Intervention: Elagolix 100 mg QD
Number of subjects: 100
Study 31650182 — intervention group
Group type: EXPERIMENTAL
Intervention: Elagolix 150 mg QD
Number of subjects: 100
Study 31650182 — intervention group
Group type: EXPERIMENTAL
Intervention: Elagolix 200 mg QD
Number of subjects: 100
Study 31650182 — intervention group
Group type: EXPERIMENTAL
Intervention: Elagolix 100 mg BID
Number of subjects: 100
Study 31650182 — intervention group
Group type: EXPERIMENTAL
Intervention: Elagolix 200 mg BID
Number of subjects: 100
Study 31650182 — intervention group
Group type: EXPERIMENTAL
Intervention: Elagolix 300 mg BID
Number of subjects: 100
Study 31650182 — intervention group
Group type: EXPERIMENTAL
Intervention: Elagolix 300 mg BID plus E2/NETA 1/0.5 mg QD
Number of subjects: 100
Study 30834932 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioural e‐learning intervention to support nurses in managing interruptions during medication administration
Number of subjects: 806
Study 30834932 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioural strategies (engagement and multitasking)
Number of subjects: 806
Study 30834932 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard practice)
Number of subjects: 806
Study 28680858 — intervention group
Group type: EXPERIMENTAL
Intervention: Agarose bead instillation (sterile)
Number of subjects: 0
Study 28680858 — intervention group
Group type: COMPARATOR
Intervention: P. aeruginosa-loaded beads
Number of subjects: 0
Study 26799904 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual Reality Exposure Therapy (VRET)
Number of subjects: 0
Study 26799904 — intervention group
Group type: COMPARATOR
Intervention: Control Exposure Therapy (CET)
Number of subjects: 0
Study 23944299 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasal intermittent positive-pressure ventilation (IPPV)
Number of subjects: 1009
Study 23944299 — intervention group
Group type: COMPARATOR
Intervention: Nasal continuous positive airway pressure (CPAP)
Number of subjects: 1009
Study 22152833 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary care sequential screening
Number of subjects: 10000
Study 22152833 — intervention group
Group type: COMPARATOR
Intervention: Primary care parallel screening
Number of subjects: 10000
Study 22152833 — intervention group
Group type: COMPARATOR
Intervention: Midwife care screening
Number of subjects: 10000
Study 19745565 — intervention group
Group type: EXPERIMENTAL
Intervention: Microdose of nicardipine (100 microg)
Number of subjects: 6
Study 19745565 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical dose of nicardipine (20 mg)
Number of subjects: 6
Study 19745565 — intervention group
Group type: EXPERIMENTAL
Intervention: In vitro metabolites of nicardipine
Number of subjects: 6
Study 16504861 — intervention group
Group type: EXPERIMENTAL
Intervention: Platelet-rich fibrin (PRF) with freeze-dried bone allograft (FDBA)
Number of subjects: 9
Study 16504861 — intervention group
Group type: COMPARATOR
Intervention: Freeze-dried bone allograft (FDBA) without PRF
Number of subjects: 9
Study 12576412 — intervention group
Group type: EXPERIMENTAL
Intervention: Isometric handgrip exercise (30% of maximum)
Number of subjects: 24
Study 12576412 — intervention group
Group type: EXPERIMENTAL
Intervention: Cold pressor test
Number of subjects: 24
Study 12576412 — intervention group
Group type: EXPERIMENTAL
Intervention: Maximal treadmill exercise
Number of subjects: 24
Study 10686190 — intervention group
Group type: EXPERIMENTAL
Intervention: r-hFSH (Gonal-F)
Number of subjects: 278
Study 10686190 — intervention group
Group type: COMPARATOR
Intervention: u-hFSH HP (Metrodin HP)
Number of subjects: 278
Study 1794430 — intervention group
Group type: EXPERIMENTAL
Intervention: Tropicamide 1% in micro drop formulation (50 micrograms tropicamide)
Number of subjects: 60
Study 1794430 — intervention group
Group type: EXPERIMENTAL
Intervention: Tropicamide 1% in combination with phenylephrine 10%
Number of subjects: 60
Study 1794430 — intervention group
Group type: COMPARATOR
Intervention: Micro drops of tropicamide 0.5% (25 micrograms tropicamide)
Number of subjects: 60
Study 1794430 — intervention group
Group type: COMPARATOR
Intervention: Standard 'minim' drop size (26 microliters)
Number of subjects: 60
Study 1794430 — intervention group
Group type: COMPARATOR
Intervention: Micro drop of five microliters
Number of subjects: 60
Study 6403956 — intervention group
Group type: EXPERIMENTAL
Intervention: Co-dergocrine mesylate 4.5 mg once daily
Number of subjects: 20
Study 6403956 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 31702797 — intervention group
Group type: EXPERIMENTAL
Intervention: NIH prevention research measuring a leading cause of death as an outcome or exposure
Number of subjects: 11082
Study 31702797 — intervention group
Group type: EXPERIMENTAL
Intervention: NIH prevention research measuring a leading risk factor for death
Number of subjects: 11082
Study 31702797 — intervention group
Group type: EXPERIMENTAL
Intervention: NIH prevention research measuring a leading risk factor for disability-adjusted life-years lost
Number of subjects: 11082
Study 31702797 — intervention group
Group type: EXPERIMENTAL
Intervention: Involvement of randomized clinical trials in NIH prevention research
Number of subjects: 11082
Study 31702797 — intervention group
Group type: EXPERIMENTAL
Intervention: Involvement of multiple leading causes or risk factors in NIH prevention research
Number of subjects: 11082
Study 31702797 — intervention group
Group type: EXPERIMENTAL
Intervention: Involvement of multiple risk factors in NIH prevention research
Number of subjects: 11082
Study 30265640 — intervention group
Group type: EXPERIMENTAL
Intervention: Reverse half hitch alternating-post (RHAP) knots
Number of subjects: 21
Study 30265640 — intervention group
Group type: COMPARATOR
Intervention: Square knots
Number of subjects: 21
Study 26066701 — intervention group
Group type: EXPERIMENTAL
Intervention: High-span APAP (range 4-15cmH2O, n=38)
Number of subjects: 76
Study 26066701 — intervention group
Group type: COMPARATOR
Intervention: Low-span APAP (range 8-12cmH2O, n=38)
Number of subjects: 76
Study 24658985 — intervention group
Group type: EXPERIMENTAL
Intervention: Supine position (Group A)
Number of subjects: 119
Study 24658985 — intervention group
Group type: COMPARATOR
Intervention: Prone position (Group B)
Number of subjects: 119
Study 22512698 — intervention group
Group type: EXPERIMENTAL
Intervention: 500 mg olive leaf extract tablet taken orally once daily
Number of subjects: 79
Study 22512698 — intervention group
Group type: COMPARATOR
Intervention: Matching placebo
Number of subjects: 79
Study 22512698 — intervention group
Group type: EXPERIMENTAL
Intervention: Olive leaf extract
Number of subjects: 79
Study 22512698 — intervention group
Group type: COMPARATOR
Intervention: Intestine without olive leaf treatment
Number of subjects: 79
Study 20220418 — intervention group
Group type: EXPERIMENTAL
Intervention: CT scanning
Number of subjects: 402
Study 20220418 — intervention group
Group type: COMPARATOR
Intervention: Dynamic radiographs
Number of subjects: 402
Study 18722573 — intervention group
Group type: EXPERIMENTAL
Intervention: Hospital clinic
Number of subjects: 76
Study 18722573 — intervention group
Group type: COMPARATOR
Intervention: Private office
Number of subjects: 76
Study 16013899 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupropion SR 150 mg daily
Number of subjects: 41
Study 16013899 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 41
Study 11910049 — intervention group
Group type: EXPERIMENTAL
Intervention: Lean beef enriched in oleic acid
Number of subjects: 10
Study 11910049 — intervention group
Group type: COMPARATOR
Intervention: Commercial beef
Number of subjects: 10
Study 11910049 — intervention group
Group type: EXPERIMENTAL
Intervention: Lean beef
Number of subjects: 10
Study 11910049 — intervention group
Group type: EXPERIMENTAL
Intervention: Low habitual beef intake
Number of subjects: 10
Study 11910049 — intervention group
Group type: EXPERIMENTAL
Intervention: High habitual beef intake
Number of subjects: 10
Study 11910049 — intervention group
Group type: EXPERIMENTAL
Intervention: Additional dietary beef
Number of subjects: 10
Study 10493677 — intervention group
Group type: EXPERIMENTAL
Intervention: Bath Ankylosing Spondylitis Functional Index (BASFI)
Number of subjects: 79
Study 10493677 — intervention group
Group type: EXPERIMENTAL
Intervention: Dougados Functional Index (DFI)
Number of subjects: 79
Study 10493677 — intervention group
Group type: EXPERIMENTAL
Intervention: Health Assessment Questionnaire - Specific (HAQ-S)
Number of subjects: 79
Study 10493677 — intervention group
Group type: COMPARATOR
Intervention: Placebo control group (patients who withdrew due to flare)
Number of subjects: 79
Study 8941114 — intervention group
Group type: EXPERIMENTAL
Intervention: MRI
Number of subjects: 24
Study 8941114 — intervention group
Group type: COMPARATOR
Intervention: Angiography
Number of subjects: 24
Study 8941114 — intervention group
Group type: COMPARATOR
Intervention: CT
Number of subjects: 24